Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study

被引：0
|
作者：
Pradhan, Richeek [1 ]
Azoulay, Laurent [1 ]
Platt, Robert W. [2 ]
Yu, Oriana H. Y. [3 ]
机构：
[1] McGill Univ, Montreal, PQ, Canada
[2] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada
[3] Jewish Gen Hosp, Lady Davis Inst, Ctr Clin Epidemiol, Montreal, PQ, Canada
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
55
引用
收藏
页码：13 / 13
页数：1
相关论文
共 50 条
  • [41] Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes
    Mkele, Gail
    JOURNAL OF ENDOCRINOLOGY METABOLISM AND DIABETES OF SOUTH AFRICA, 2015, 20 (01) : 64 - 66
  • [42] Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes
    Scheen, Andre J.
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (04) : 505 - 524
  • [43] Cost Effectiveness of Dipeptidyl Peptidase-4 Inhibitors for Type 2 Diabetes
    Geng, Jinsong
    Yu, Hao
    Mao, Yiwei
    Zhang, Peng
    Chen, Yingyao
    PHARMACOECONOMICS, 2015, 33 (06) : 581 - 597
  • [44] Effect of dipeptidyl peptidase IV inhibitors, thiazolidinedione, and sulfonylurea on osteoporosis in patients with type 2 diabetes: population-based cohort study
    Yang, B. R.
    Cha, S. H.
    Lee, K. E.
    Kim, J. W.
    Lee, J.
    Shin, K-H
    OSTEOPOROSIS INTERNATIONAL, 2021, 32 (09) : 1705 - 1712
  • [45] Peptidomimetic structure of dipeptidyl peptidase-4 inhibitors and the risk of sulfonylurea-induced severe hypoglycemia: A population-based cohort study
    Dimakos, Jenny
    Cui, Ying
    Platt, Robert
    Renoux, Christel
    Filion, Kristian
    Douros, Antonios
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 286 - 286
  • [46] Candidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes
    Jang, Yun-Mi
    Kim, Dong-Lim
    DIABETES & METABOLISM JOURNAL, 2011, 35 (02) : 117 - 118
  • [47] Do Dipeptidyl Peptidase-4 Inhibitors Increase the Risk of Heart Failure in Patients with Type 2 Diabetes?
    Hassanabad, Mortaza Fatehi
    Hassanabad, Ali Fatehi
    Fatehi, Mohammad
    CURRENT DIABETES REVIEWS, 2022, 18 (08)
  • [48] Dipeptidyl peptidase-4 inhibitors reduce the risk of developing autoimmune diseases in patients with type 2 diabetes
    Idris, Iskandar
    DIABETES OBESITY & METABOLISM, 2014, 16 (01): : 95 - 96
  • [49] Peptidomimetic structure of dipeptidyl peptidase-4 inhibitors and the risk of sulfonylurea-induced severe hypoglycemia: a population-based cohort study
    Dimakos, J.
    Cui, Y.
    Platt, R.
    Renoux, C.
    Filion, K.
    Douros, A.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (SUPPL 1) : S8 - S8
  • [50] Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes
    Mkele, Gail
    SOUTH AFRICAN FAMILY PRACTICE, 2013, 55 (06) : 508 - 510
12345